CB1 inverse agonist 1
CAS No. 852315-00-5
CB1 inverse agonist 1( —— )
Catalog No. M32826 CAS No. 852315-00-5
CB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 255 | Get Quote |
|
| 10MG | 375 | Get Quote |
|
| 25MG | 545 | Get Quote |
|
| 50MG | 762 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 500MG | 2043 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCB1 inverse agonist 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCB1 inverse agonist 1 (MRL-650) is an orally active and selective CB1 agonist. The IC50s for CB1 and CB2 are 7.5 nM and 4100 nM, respectively.
-
DescriptionMRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC50s of 7.5 nM and 4100 nM for CB1 and CB2 receptors, respectively. Anorexigenic effects.
-
In Vitro——
-
In VivoMRL-650 (Compound 14; 0.3, 1, or 3 mg/kg)inhibits feeding in a dose-dependent manner. The pharmacokinetic profile of CB1 inverse agonist 1 is evaluated in Sprague-Dawley rats, C57BL/6 mice, beagles, and rhesus macaques with t1/2 of >8, >8, >24, and 22 h, respectively.Animal Model:Rat Dosage:0.3, 1, or 3 mg/kg Administration:PO Result:Inhibited feeding in a dose-dependent manner. 3 mg/kg decreased cumulative food intake from 2 h post-dosing. Decreased overnight body weight gain compared to vehicle treatment at all dosing levels.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number852315-00-5
-
Formula Weight514.79
-
Molecular FormulaC25H18Cl3N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(C)=O)C=1C=2C(=NC(=C(C2)C3=CC=C(Cl)C=C3)C4=C(Cl)C=C(Cl)C=C4)N(C)C(=O)C1C(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Tetrahydrocannabivar...
Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.
-
CB2 receptor agonist...
CB2 receptor agonist 2 is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor, Ki = 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2.
-
AEF0117
AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.
Cart
sales@molnova.com